May 7, 2026
•
7 min read
Plus: ARPA-H’s AI research engine, digital twins for donor lungs, and OpenBind’s new drug-design dataset
May 4, 2026
6 min read
Plus: a world model that simulates drug and lifestyle interventions person by person, perturbation prediction clears the bar, and a physics lab trains one model on DNA, RNA, and protein.
May 2, 2026
3 min read
Billion-dollar deals, enzymes nature never made, and virtual patients built from 7.2 million real ones.
Apr 29, 2026
Plus: Lilly’s $2.25B bet on AI-designed gene insertion, a literature agent that reads the pictures, and the FDA takes aim at the clinical trial bottleneck.
Apr 26, 2026
8 min read
Eight signals to help you understand what is actually happening beneath the weekly flood of papers, deals, tools, and demos.
Plus: a 24-year-old redesigns Keytruda, breast cells have a hidden “mechanical age,” and OpenAI gives its models to every US clinician for free.
Apr 23, 2026
Plus: virtual patients from 7.2 million real ones, AI antibiotics vs. reality, and clinical biomarkers hiding in your smartwatch.
Apr 19, 2026
Plus: OpenAI ships its first biology model and signs Novo Nordisk, a step toward virtual cells that explain the biology, and a brain-reading beanie with 100,000 sensors.
Apr 16, 2026
Plus: Goodfire takes on two million variants stuck in diagnostic limbo, AWS enters AI drug design, and five things the head of Isomorphic Labs told me
Apr 12, 2026
15 min read
Plus: an AI that reads heart fat predicts failure five years out, Medra opens America's largest autonomous lab, and Genentech tests AI agents on 100 biology tasks.
